Cryopyrin-associated periodic syndrome epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
Sahar Memar Montazerin (talk | contribs)
Created page with "__NOTOC__ {{Cryopyrin-associated periodic syndrom}} {{CMG}}; {{AE}} {{Sahar}} ==Overview== ==Epidemiology and Demographics== ===Incidence=== *The incidence Cryopyrin-associa..."
 
Sahar Memar Montazerin (talk | contribs)
No edit summary
Line 7: Line 7:
==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence Cryopyrin-associated periodic syndrom is approximately 0.003 per 100,000 individuals aged 16 years old or younger worldwide.<ref name="LainkaNeudorf2010">{{cite journal|last1=Lainka|first1=E.|last2=Neudorf|first2=U.|last3=Lohse|first3=P.|last4=Timmann|first4=C.|last5=Bielak|first5=M.|last6=Stojanov|first6=S.|last7=Huss|first7=K.|last8=Kries|first8=R. von|last9=Niehues|first9=T.|title=Analysis of Cryopyrin-Associated Periodic Syndromes (CAPS) in German Children: Epidemiological, Clinical and Genetic Characteristics|journal=Klinische Pädiatrie|volume=222|issue=06|year=2010|pages=356–361|issn=0300-8630|doi=10.1055/s-0030-1265181}}</ref>
*The incidence cryopyrin-associated periodic syndrom is approximately 0.0343 per 100,000 individuals aged 16 years old or younger worldwide.<ref name="LainkaNeudorf2010">{{cite journal|last1=Lainka|first1=E.|last2=Neudorf|first2=U.|last3=Lohse|first3=P.|last4=Timmann|first4=C.|last5=Bielak|first5=M.|last6=Stojanov|first6=S.|last7=Huss|first7=K.|last8=Kries|first8=R. von|last9=Niehues|first9=T.|title=Analysis of Cryopyrin-Associated Periodic Syndromes (CAPS) in German Children: Epidemiological, Clinical and Genetic Characteristics|journal=Klinische Pädiatrie|volume=222|issue=06|year=2010|pages=356–361|issn=0300-8630|doi=10.1055/s-0030-1265181}}</ref>
===Prevalence===
===Prevalence===
*The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
*The prevalence of cryopyrin-associated periodic syndrom is approximately 0.1 per 100,000 individuals worldwide.<ref name="MehrAllen2016">{{cite journal|last1=Mehr|first1=Sam|last2=Allen|first2=Roger|last3=Boros|first3=Christina|last4=Adib|first4=Navid|last5=Kakakios|first5=Alyson|last6=Turner|first6=Paul J|last7=Rogers|first7=Maureen|last8=Zurynski|first8=Yvonne|last9=Singh-Grewal|first9=Davinder|title=Cryopyrin-associated periodic syndrome in Australian children and adults: Epidemiological, clinical and treatment characteristics|journal=Journal of Paediatrics and Child Health|volume=52|issue=9|year=2016|pages=889–895|issn=10344810|doi=10.1111/jpc.13270}}</ref>
*In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
*The prevalence of [disease/malignancy] is estimated to be [number] cases annually.


===Case-fatality rate/Mortality rate===
===Case-fatality rate/Mortality rate===

Revision as of 15:15, 2 July 2019

Template:Cryopyrin-associated periodic syndrom

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]

Overview

Epidemiology and Demographics

Incidence

  • The incidence cryopyrin-associated periodic syndrom is approximately 0.0343 per 100,000 individuals aged 16 years old or younger worldwide.[1]

Prevalence

  • The prevalence of cryopyrin-associated periodic syndrom is approximately 0.1 per 100,000 individuals worldwide.[2]

Case-fatality rate/Mortality rate

  • In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
  • The case-fatality rate/mortality rate of [disease name] is approximately [number range].

Age

  • Patients of all age groups may develop [disease name].
  • The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
  • [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
  • [Chronic disease name] is usually first diagnosed among [age group].
  • [Acute disease name] commonly affects [age group].

Race

  • There is no racial predilection to [disease name].
  • [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].

Gender

  • [Disease name] affects men and women equally.
  • [Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.

Region

  • The majority of [disease name] cases are reported in [geographical region].
  • [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].

Developed Countries

Developing Countries

References

  1. Lainka, E.; Neudorf, U.; Lohse, P.; Timmann, C.; Bielak, M.; Stojanov, S.; Huss, K.; Kries, R. von; Niehues, T. (2010). "Analysis of Cryopyrin-Associated Periodic Syndromes (CAPS) in German Children: Epidemiological, Clinical and Genetic Characteristics". Klinische Pädiatrie. 222 (06): 356–361. doi:10.1055/s-0030-1265181. ISSN 0300-8630.
  2. Mehr, Sam; Allen, Roger; Boros, Christina; Adib, Navid; Kakakios, Alyson; Turner, Paul J; Rogers, Maureen; Zurynski, Yvonne; Singh-Grewal, Davinder (2016). "Cryopyrin-associated periodic syndrome in Australian children and adults: Epidemiological, clinical and treatment characteristics". Journal of Paediatrics and Child Health. 52 (9): 889–895. doi:10.1111/jpc.13270. ISSN 1034-4810.

Template:WH Template:WS